Cormorant Asset Management, LP Moon Lake Immunotherapeutics Transaction History
Cormorant Asset Management, LP
- $628 Million
- Q3 2025
A detailed history of Cormorant Asset Management, LP transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Cormorant Asset Management, LP holds 1,994,173 shares of MLTX stock, worth $25.5 Million. This represents 2.28% of its overall portfolio holdings.
Number of Shares
1,994,173
Previous 8,494,151
76.52%
Holding current value
$25.5 Million
Previous $401 Million
96.43%
% of portfolio
2.28%
Previous 40.43%
Shares
5 transactions
Others Institutions Holding MLTX
# of Institutions
182Shares Held
38.4MCall Options Held
4.13MPut Options Held
1.54M-
Bvf Inc San Francisco, CA19.8MShares$252 Million7.66% of portfolio
-
Avoro Capital Advisors LLC New York, NY2MShares$25.5 Million0.2% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.7MShares$21.7 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.5MShares$19.2 Million0.02% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY965KShares$12.3 Million0.05% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $472M
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...